Annual conference returns to Washington, D.C., Sept. 15-16; addresses challenges in establishing a new paradigm for how evidence of efficacy and safety is generated. CGIC 2026 convenes leaders across ...
TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
TUCSON, Ariz., and AMSTERDAM, May 19, 2026 — Critical Path Institute® (C-Path) today announced the launch of the New Approach Methodologies Developer Coalition (NAMs-DC), a precompetitive, ...
Critical Path Institute® (C-Path) today announced new leadership on its Board of Directors. Karen Bernstein, Ph.D., ...
Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled "Transforming Drug Development for Neurological Disorders: Proceedings from a ...
Critical Path Institute (C-Path), a leading global nonprofit committed to expediting drug development through the acceleration of regulatory-endorsed solutions, today announced a newly formalized ...
Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...
Annual conference returns to Washington, D.C., Sept. 15-16; addresses challenges in establishing a new paradigm for how evidence of efficacy and safety is generated. TUCSON, Ariz., June 9, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results